According to Ipsen's press release, the interim data from the long-term open-label ELATIVE study, which included over three years of follow-up with 115 patients suffering from primary biliary cholangitis (PBC), demonstrate that Iqirvo enables sustainable improvements in cholestasis biomarkers and stabilization of fibrosis markers. At week 182, 72% of patients treated with Iqirvo showed a sustained biochemical response, with a 47% reduction in alkaline phosphatase levels compared to baseline.
Improvements in Symptoms
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The results from the ELATIVE trial also indicate that patients experiencing moderate to severe fatigue observed an improvement in their symptoms, and similar outcomes were noted for pruritus. These positive effects are accompanied by a favorable long-term tolerance profile, with no new safety concerns, according to the press release.
Potential Role in Mitochondrial Function
The new data from the ELATIVE trial suggest that Iqirvo, a PPAR ?/? receptor agonist, could play a significant role in improving pathways associated with fatigue and mitochondrial function. Iqirvo is currently approved for the treatment of PBC in combination with ursodeoxycholic acid in adults with inadequate response or as monotherapy in patients intolerant to UDCA, in several regions, including the United States and the EU.
"En 2025, Ipsen a enregistré une croissance solide de son chiffre d'affaires et de son résultat opérationnel."
Ipsen a publié ses résultats 2025 et T4 2025: chiffre d'affaires de 3 675,9 millions d'euros, croissance YoY de 8,1%; Résultat opérationnel des activités de 1 294,1 millions d'euros, marge de 35,2%; Résultat net consolidé IFRS de 444,5 millions d'euros; Bénéfice dilué par action IFRS de 5,32 euros; Cash-flow libre de 1 000,6 millions d'euros; Dividende par action de 1,40 euro.
Outlook / guidance
Expected revenue: Une croissance des ventes totales supérieure à 13,0 % à taux de change constant en 2026
Management commentary: Ipsen prévoit en 2026 une croissance des ventes totales supérieure à 13,0% à taux de change constant et une marge opérationnelle des activités supérieure à 35,0%.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
